Gene correction treats hereditary lung and liver disease for the first time

· Science

Alpha-1 antitrypsin deficiency (AATM) is a congenital metabolic disorder caused by a genetic defect that makes the body produce the protective protein alpha-1 antitrypsin (AAT) incorrectly. The faulty protein primarily damages the lungs and the liver, where it can lead to serious conditions including pulmonary emphysema and liver disease. According to the report, the condition has now been successfully treated for the first time using gene correction. The result marks a step for gene-editing approaches aimed at inherited metabolic diseases, where a single corrected gene could address damage across multiple organs rather than treating symptoms one organ at a time. Details of the trial design, patient numbers and durability of the effect were not provided in the item.

Why it matters：A one-time genetic fix for a multi-organ inherited disease would shift treatment from lifelong protein replacement toward curative editing, a template that other monogenic metabolic disorders could follow.

Key points

  • The disorder is caused by a defect in production of the protein AAT.
  • Damage centers on the lungs and liver.
  • The report calls this the first successful treatment of the disease by gene correction.

Sources (original reporting)

More stories from this day